Pharmaceutical company Reviva Pharmaceuticals Inc on Friday announced a successful a pre-Investigational New Drug (IND) Application meeting with the US Food and Drug Administration (FDA) for the IND development plan of brilaroxazine as well as guidance for launch of its phase 2 clinical study.
The company added that the US FDA has recently granted Orphan Drug Designation to brilaroxazine for treating patients with Idiopathic Pulmonary Fibrosis (IPF).
In the Pre-IND Meeting, the US FDA has reviewed the company's brilaroxazine IND enabling preclinical data and clinical phase 1 study results and phase 2 study plan for IPF. The US FDA addressed the questions and provided guidance on the brilaroxazine clinical development plan for IPF.
According to the company, Brilaroxazine is a new chemical entity (NCE) that acts on serotonin signaling pathways. Serotonin signaling derived from activated 5-HT2A/2B/7 receptors in the lung mediates inflammation, fibrosis and proliferation, and pulmonary hypertension. Brilaroxazine is a potent inhibitor of the 5-HT2A/2B/7 receptors and attenuates these functional changes in highly recognized translational animal models proven to emulate IPF and PAH conditions in humans.
IPF is a progressive, debilitating and fatal lung disease characterised by inflammation and fibrosis of the lungs, hindering the ability to process oxygen and causing shortness of breath.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Halia Therapeutics collaborates with Canary Speech
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007
Sanofi reports FDA approval for Dupixent in paediatric EoE treatment